SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Nectar Lifesciences board approves unaudited financial results

14 Nov 2019 Evaluate

Nectar Lifesciences has informed that the Board of Directors of the Company at their meeting held today duly approved and took on record the Unaudited Standalone & Consolidated Financial results for the quarter and half year ended on September 30, 2019, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

The above information is a part of company’s filings submitted to BSE.

Nectar Lifesciences Share Price

12.66 0.25 (2.01%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×